These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 21747136)

  • 1. [Genetic defects and disorders at the neuromuscular junction].
    Ohno K
    Brain Nerve; 2011 Jul; 63(7):669-78. PubMed ID: 21747136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular bases and therapeutic strategies in defective neuromuscular transmissions: lessons learned from a prototypical synapse].
    Ohno K; Ito M; Masuda A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Aug; 29(4):145-51. PubMed ID: 19764481
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Editorial introduction: from the structure and functions of the neuromuscular junction to the diseases].
    Takamori M
    Brain Nerve; 2011 Jul; 63(7):635-40. PubMed ID: 21747132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of collagen Q in MuSK antibody-positive myasthenia gravis.
    Ohno K; Otsuka K; Ito M
    Chem Biol Interact; 2016 Nov; 259(Pt B):266-270. PubMed ID: 27119269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenia Gravis: From the Viewpoint of Pathogenicity Focusing on Acetylcholine Receptor Clustering, Trans-Synaptic Homeostasis and Synaptic Stability.
    Takamori M
    Front Mol Neurosci; 2020; 13():86. PubMed ID: 32547365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myasthenia gravis experimentally induced with muscle-specific kinase.
    Shigemoto K; Kubo S; Jie C; Hato N; Abe Y; Ueda N; Kobayashi N; Kameda K; Mominoki K; Miyazawa A; Ishigami A; Matsuda S; Maruyama N
    Ann N Y Acad Sci; 2008; 1132():93-8. PubMed ID: 18096854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Congenital myasthenic syndromes: phenotypic expression and pathophysiological characterisation].
    Andreux F; Hantaï D; Eymard B
    Rev Neurol (Paris); 2004 Feb; 160(2):163-76. PubMed ID: 15034473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission.
    Müller JS; Mihaylova V; Abicht A; Lochmüller H
    Expert Rev Mol Med; 2007 Aug; 9(22):1-20. PubMed ID: 17686188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRP4 third β-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner.
    Ohkawara B; Cabrera-Serrano M; Nakata T; Milone M; Asai N; Ito K; Ito M; Masuda A; Ito Y; Engel AG; Ohno K
    Hum Mol Genet; 2014 Apr; 23(7):1856-68. PubMed ID: 24234652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms underlying the formation of neuromuscular junction].
    Higuchi O; Yamanashi Y
    Brain Nerve; 2011 Jul; 63(7):649-55. PubMed ID: 21747134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular regulation of postsynaptic differentiation at the neuromuscular junction.
    Madhavan R; Peng HB
    IUBMB Life; 2005 Nov; 57(11):719-30. PubMed ID: 16511964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MuSK levels differ between adult skeletal muscles and influence postsynaptic plasticity.
    Punga AR; Maj M; Lin S; Meinen S; Rüegg MA
    Eur J Neurosci; 2011 Mar; 33(5):890-8. PubMed ID: 21255125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Congenital myasthenic syndromes].
    Ohno K
    Rinsho Shinkeigaku; 2012; 52(11):1159-61. PubMed ID: 23196549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific binding of collagen Q to the neuromuscular junction is exploited to cure congenital myasthenia and to explore bases of myasthenia gravis.
    Ohno K; Ito M; Kawakami Y; Krejci E; Engel AG
    Chem Biol Interact; 2013 Mar; 203(1):335-40. PubMed ID: 22981737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital myasthenic syndromes: progress over the past decade.
    Engel AG; Ohno K; Sine SM
    Muscle Nerve; 2003 Jan; 27(1):4-25. PubMed ID: 12508290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collagen Q and anti-MuSK autoantibody competitively suppress agrin/LRP4/MuSK signaling.
    Otsuka K; Ito M; Ohkawara B; Masuda A; Kawakami Y; Sahashi K; Nishida H; Mabuchi N; Takano A; Engel AG; Ohno K
    Sci Rep; 2015 Sep; 5():13928. PubMed ID: 26355076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The postsynaptic submembrane machinery at the neuromuscular junction: requirement for rapsyn and the utrophin/dystrophin-associated complex.
    Banks GB; Fuhrer C; Adams ME; Froehner SC
    J Neurocytol; 2003; 32(5-8):709-26. PubMed ID: 15034263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of the neuromuscular junction.
    Witzemann V
    Cell Tissue Res; 2006 Nov; 326(2):263-71. PubMed ID: 16819627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Congenital myasthenic syndromes: multiple molecular targets at the neuromuscular junction.
    Engel AG; Ohno K; Shen XM; Sine SM
    Ann N Y Acad Sci; 2003 Sep; 998():138-60. PubMed ID: 14592871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
    Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
    PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.